TauRx Pharmaceuticals Ltd, 2015-06-01: Company press release of 1 June 2015 in which TauRx explains that the oxidised methylthioninium chloride (ordinary methylene blue) had limited bioavailability at high dose, and that it developed LMTX, a stable reduced form, as 'a novel chemical entity'.
We were able to show that the problem is the redox state of the MT moiety, and we had to discover how to produce MT in a stable reduced form, which we have done with LMTX
2
TauRx Pharmaceuticals Ltd, 2015-06-01: Company press release of 1 June 2015 in which TauRx explains that the oxidised methylthioninium chloride (ordinary methylene blue) had limited bioavailability at high dose, and that it developed LMTX, a stable reduced form, as 'a novel chemical entity'. C3 public explanation by the company (record field for the quote attribution: the passage is attributed to Professor Claude Wischik in the release; it is set as direct speech). Text: earlier Phase 2 dosing in the oxidised MT+ form 'as we did using the chloride salt (methylthionium chloride, MTC, commonly known as methylene blue)' limited bioavailability; 'we had to discover how to produce MT in a stable reduced form, which we have done with LMTX'; 'This is a novel chemical entity that is able to deliver MT to the brain more efficiently.' Release dated 1 June 2015, issued from Aberdeen and Singapore. text_file=B_6.txt Study type: other.
